Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity

FASEB Journal

Volumn 27, Issue 8, 2013, Pages 2946-2956

  Khan, Md Abdul Hye ^a   Liu, Jing ^b   Kumar, Ganesh ^b   Skapek, Stephen X ^b   Falck, John R ^b   Imig, John D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Chemotherapeutics; Eicosanoids

Indexed keywords

CASPASE 12; CASPASE 3; CISPLATIN; CREATININE; EPOXYICOSATRIENOIC ACID; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; KIDNEY INJURY MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYL BETA GLUCOSAMINIDASE; PROTEIN BCL 2; 11,12-EPOXY-5,8,14-EICOSATRIENOIC ACID; COPPER ZINC SUPEROXIDE DISMUTASE; CROSS LINKING REAGENT; DIHOMO GAMMA LINOLENIC ACID; SUPEROXIDE DISMUTASE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; ENDOPLASMIC RETICULUM STRESS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; KIDNEY INJURY; KIDNEY PARENCHYMA; MALE; NEPHRITIS; NEPHROTOXICITY; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; URINE LEVEL; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CELL SURVIVAL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; KIDNEY; KIDNEY DISEASES; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXICITY; TUMOR CELL LINE; WISTAR KYOTO RAT;

RATTUS;

8,11,14-EICOSATRIENOIC ACID; ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; BLOOD UREA NITROGEN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CREATININE; CROSS-LINKING REAGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; HEK293 CELLS; HELA CELLS; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, INBRED WKY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPEROXIDE DISMUTASE; VASODILATOR AGENTS;

EID: 84881128520     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-218040     Document Type: Article

References (51)

1. Bongers, M. L., Coupé, V. M., Jansma, E. P., Smit, E. F., and Uyl-de Groot, C. A. (2012) Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics 30, 17-34
2. Levy, A. R., Johnston, K. M., Sambrook, J., Donato, B., Penrod, J. R., Corral, M., and Chasen, M. (2011) Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. Curr. Med. Res. Opin. 27, 2253-2259
3. Wang, D., and Lippard, S. J. (2005) Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307-320
4. Kintzel, P. E. (2001) Anticancer drug-induced kidney disorders. Drug Safety 24, 19-38
5. Miller, R. P., Tadagavadi, R. K., Ramesh, G., and Reeves, W. B. (2010) Mechanisms of cisplatin nephrotoxicity. Toxins 2, 2490-2518
6. Sánchez-González, P. D., López-Hernández, F. J., López-Novoa, J. M., and Morales, A. I. (2011) An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit. Rev. Toxicol. 41, 803-821
7. Perazella, M. A., and Moeckel, G. W. (2010) Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin. Nephrol. 30, 570-581
8. Lieberthal, W., Triaca, V., and Levine, J. (1996) Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am. J. Physiol. 270, F700-F708
9. Ma, H., Jones, K. R., Guo, R., Xu, P., Shen, Y., and Ren, J. (2010) Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress. Clin. Exp. Pharmacol. Physiol. 37, 460-465
10. Pabla, N., and Dong, Z. (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 73, 994-1007
11. Imig, J. D. (2012) Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol. Rev. 92, 101-130
12. Imig, J. D., and Hammock, B. D. (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8, 794-805
13. Olearczyk, J. J., Quigley, J. E., Mitchell, B. C., Yamamoto, T., Kim, I. H., Newman, J. W., Luria, A., Hammock, B. D., and Imig, J. D. (2009) Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin. Sci. (Lond.) 116, 61-70
14. Elmarakby, A. A., Faulkner, J., Al-Shabrawey, M., Wang, M. H., Maddipati, K. R., and Imig, J. D. (2011) Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocininduced type 1 diabetes. Am. J. Physiol. 301, R1307-R1317
15. Yang, B., Graham, L., Dikalov, S., Mason, R. P., Falck, J. R., Liao, J. K., and Zeldin, D. C. (2001) Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol. Pharmacol. 60, 310-320
16. Zhao, G., Wang, J., Xu, X., Jing, Y., Tu, L., Li, X., Chen, C., Cianflone, K., Wang, P., Dackor, R. T., Zeldin, D. C., and Wang, D. W. (2012) Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-+-induced injury. J. Lipid Res. 2012, 53, 456-466
17. Liu, L., Chen, C., Gong, W., Li, Y., Edin, M. L., Zeldin, D. C., and Wang, D. W. (2011) Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide. J. Pharmacol. Exp. Ther. 339, 451-463
18. Imig, J. D. (2010) Targeting epoxides for organ damage in hypertension. J. Cardiovasc. Pharmacol. 56, 329-335
19. King, L. M., Gainer, J. V., David, G. L., Dai, D., Goldstein, J. A., Brown, N. J., and Zeldin, D. C. (2005) Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet. Genomics 15, 7-13
20. Morisseau, C., and Hammock, B. D. (2005) Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 45, 311-333
21. Falck, J. R., Kodela, R., Manne, R., Atcha, K. R., Puli, N., Dubasi, N., Manthati, V. L., Capdevila, J. H., Yi, X. Y., Goldman, D. H., Morisseau, C., Hammock, B. D., and Campbell, W. B. (2009) 14,15-epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. J. Med. Chem. 52, 5069-5075
22. Imig, J. D., Elmarakby, A., Nithipatikom, K., Wei, S., Capdevila, J. H., Tuniki, V. R., Sangras, B., Anjaiah, S., Manthati, V. L., Sudarshan, R. D., and Falck, J. R. (2010) Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. Front. Physiol. 1, 157
23. Batchu, S. N., Lee, S. B., Qadhi, R. S., Chaudhary, K. R., El-Sikhry, H., Kodela, R., Falck, J. R., and Seubert, J. M. (2011) Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury. Br. J. Pharmacol. 162, 897-907
24. Inagi, R. (2009) Endoplasmic reticulum stress in the kidney as a novel mediator of kidney injury. Nephron. Exp. Nephrol. 112, e1-e9
25. Benoehr, P., Krueth, P., Bokemeyer, C., Grenz, A., Osswald, H., and Hartmann, J. T. (2005) Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, singleblinded, placebo-controlled trial. J. Am. Soc. Nephrol. 16, 452-458
26. Hanigan, M. H., Deng, M., Zhang, L., Taylor, P.T. Jr., and Lapus, M.G. (2005) Stress response inhibits the nephrotoxicity of cisplatin. Am. J. Physiol. Renal Physiol. 288, F125-F132
27. Seubert, J. M., Zeldin, D. C., Nithipatikom, K., and Gross, G. J. (2007) Role of epoxyeicosatrienoic acids protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 82, 50-59
28. Gross, G. J., Gauthier, K. M., Moore, J., Falck, J. R., Hammock, B. D., Campbell, W. B., and Nithipatikom, K. (2008) Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am. J. Physiol. Heart Circ. Physiol. 294, H2838-H2844
29. Imig, J. D., and Falck, J. R. (2009) Compositions and methods for the treatment of renal and cardiovascular disease. U.S. Patent 7,550,617
30. Sodhi, K., Inoue, K., Gotlinger, K. H., Canestraro, M., Vanella, L., Kim, D. H., Manthati, V. L., Koduru, S. R., Falck, J. R., Schwarzman, M. L., and Abraham, N. G. (2009) Epoxyeicosatrienoic acid agonist rescues metabolic syndrome phenotype of HO-2-null mice. J. Pharmacol. Exp. Ther. 331, 906-916
31. Parrish, A. R., Chen, G., Burghardt, R. C., Watanabe, T., Morisseau, C., and Hammock, B. D. (2009) Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol. Toxicol. 25, 217-225
32. Liu, Y., Webb, H. K., Fukushima, H., Micheli, J., Markova, S., Olson, J. L., and Kroetz, D. L. (2012) Attenuation of cisplatininduced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor B signaling. J. Pharmacol. Exp. Ther. 341, 725-734
33. Kaergel, E., Muller, D. N., Honeck, H., Theuer, J., Shagdarsuren, E., Mullally, A., Luft, F. C., and Schunck, W. H. (2002) P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension 40, 273-279
34. Marino, J. P., Jr. (2009) Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery. Curr. Top. Med. Chem. 9, 452-463
35. Jia, Z., Wang, N., Aoyagi, T., Wang, H., Liu, H., and Yang, T. (2011) Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis. Kidney Int. 79, 77-88
36. El-Beshbishy, H. A., Bahashwan, S. A., Aly, H. A., and Fakher, H. A. (2011) Abrogation of cisplatin-induced nephrotoxicity in mice by alpha lipoic acid through ameliorating oxidative stress and enhancing gene expression of antioxidant enzymes. Eur. J. Pharmacol. 668, 278-284
37. Mukhopadhyay, P., Horváth, B., Zsengellér, Z., Zielonka, J., Tanchian, G., Holovac, E., Kechrid, M., Patel, V., Stillman, I. E., Parikh, S. M., Joseph, J., Kalyanaraman, B., and Pacher, P. (2012) Cisplatin-induced nephropathy. Free Radic. Biol. Med. 52, 497-506
38. Ramesh, G., and Reeves, W. B. (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 110, 835-842
39. Faubel, S., Lewis, E. C., Reznikov, L., Ljubanovic, D., Hoke, T. S., Somerset, H., Oh, D. J., Lu, L., Klein, C. L., Dinarello, C. A., and Edelstein, C. L. (2007) Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J. Pharmacol. Exp. Ther. 322, 8-15
40. Zhang, B., Ramesh, G., Norbury, C. C., and Reeves, W. B. (2007) Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int. 72, 37-44
41. Falck, J. R., Reddy, L. M., Reddy, Y. K., Bondlela, M., Krishna, U. M., Ji, Y., Sun, J., and Liao, J. K. (2003) 11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression. Bioorg. Med. Chem. Lett. 13, 4011-4014
42. Node, K., Huo, Y., Ruan, X., Yang, B., Spiecker, M., Ley, K., Zeldin, D. C., and Liao, J. K. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-1279
43. Manhiani, M., Quigley, J. E., Knight, S. F., Tasoobshirazi, S., Moore, T., Brands, M.W., Hammock, B. D. and Imig, J. D. (2009) Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am. J. Physiol. Renal Physiol. 297, F740-F748
44. Zhao, G., Tu, L., Li, X., Yang, S., Chen, C., Xu, X., Wang, P., and Wang, D. W. (2012) Delivery of AAV2-CYP2J2 protects remnant kidney in the 5/6-nephrectomized rat via inhibition of apoptosis and fibrosis. Hum. Gene Ther. 23, 688-699
45. Cribb, A. E., Peyrou, M., Muruganandan, S., and Schneider, L. (2005) The endoplasmic reticulum in xenobiotic toxicity. Drug Metab. Rev. 37, 405-442
46. Mandic, A., Hansson, J., Linder, S., and Shoshan, M. C. (2003) Cisplatin induces endoplasmic reticulum stress and nucleusindependent apoptotic signaling. J. Biol. Chem. 278, 9100-9106
47. Peyrou, M., Hanna, P. E., and Cribb, A. E. (2007) Cisplatin, gentamicin, and p-aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys. Toxicol. Sci. 99, 346-353
48. Rabik, C. A., Fishel, M. L., Holleran, J. L., Kasza, K., Kelley, M. R.,.Egorin, M. J., and Dolan, M. E. (2008) Enhancement of cisplatin [cis-diamminedichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J. Pharmacol. Exp. Ther. 327, 442-452
49. Breckenridge, D. G., Germain, M., Mathai, J. P., Nguyen, M., and Shore, G. C. (2003) Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 22, 8608-8618
50. Park, M. S., De Leon, M., and Devarajan, P. (2002) Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J. Am. Soc. Nephrol. 13, 858-865
51. Wei, Q., Dong, G., Franklin, J., Dong, Z. (2007) The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int. 72, 53-62